StockData

Eloxx Pharmaceuticals vs X4 Pharmaceuticals

ELOX and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELOX and XFOR compare

X4 Pharmaceuticals is the larger company, worth 6.5 times as much as Eloxx Pharmaceuticals ($306M against $47.4M).

X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus −100% for Eloxx Pharmaceuticals).

Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELOXXFOR
Size and price
Market cap$47.4M$306M
Share price$11.74$3.09
Change, 1 year1067170%−15.6%
Change, 5 years−98.1%−97.7%
Beta (5Y)–1.45
Employees745
StockData Score
Total score7 (better)3
Valuation score1 (better)0
Growth score02 (better)
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/S–30.9×
P/B1.0× (better)2.2×
Growth
Revenue growth (TTM)−100%73.7% (better)
Revenue growth, 5Y average–16.7%
Profitability
Gross margin–68.8%
Operating margin–−812%
Net margin–−813%
Return on equity−54.3% (better)−80.3%
Financial health
Debt / equity0.00–
Interest coverage–−9.3×
Current ratio3.7413.22 (better)
Altman Z-score−4.60−2.11 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.8%103%
Held by insiders42.6%12.2%
Insider net buying, 12 months–−$451K
Short interest, % of float2.3%9.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.